-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" was grandly opened
There is currently no uniform treatment regimen
Tisagenlecleucel was used in the ELIANA study to treat patients with r/r B-ALL aged 3-21 years, with an objective response rate (ORR) (CR+CRi) of 82.
Among children and adolescents, 12 patients with bone marrow r/r obtained CR or CRi after a single treatment, and the ORR was 83.
In view of the results of a large number of clinical studies, Herkirensai's new drug marketing application for adult r/r B-ALL indications is actively being prepared, and at the same time, the registered clinical study in children and adolescents (3-18 years old) r/r B-ALL patients has also obtained the clinical trial implied permission of the Drug Evaluation Center of the State Drug Administration on August 19, 2022, and the clinical trial is ongoing
.
It is believed that after the approval of the Hekylon Race for marketing, it will be able to fill the gap of targeted CD19 CAR-T treatment r/r B-ALL in China and bring hope
to more patients.
Professor Wang Jianxiang concluded
that Professor Wang Ying shared in detail the research status of r/r B-ALL therapy, the application of CAR-T therapy in r/r B-ALL, and the application of Heqirensai, the first Chinese targeted CD19 CAR-T therapy drug in R/r B-ALL
.
According to the relevant research and clinical cases of Hekylon race shared by Professor Wang Ying, we are full of confidence in the future clinical application of Hekylon race in r/r B-ALL! Editor: Su Meng Typesetting: Wenting Execution: Wenting
Figure 1 Prognosis and recurrence of adult B-ALL in China
There is currently no uniform treatment regimen
Figure 2 Immunotherapy mechanism
Tisagenlecleucel was used in the ELIANA study to treat patients with r/r B-ALL aged 3-21 years, with an objective response rate (ORR) (CR+CRi) of 82.
Figure 3 The current approval status of CD19 CAR-T cell products
Figure 4 r/r ALL domestic and foreign guideline treatment recommendations
Figure 5 Results of pre-clinical studies of Herkirensai in adult B-ALL treatment
Among children and adolescents, 12 patients with bone marrow r/r obtained CR or CRi after a single treatment, and the ORR was 83.
Figure 6 Results of a preclinical study of Heckylendeux in the treatment of children and adolescents with B-ALL
In a Phase I clinical study of Hekylendsal in the treatment of adult r/r B-ALL, 9 patients had an ORR of 88.
9%
within 3 months.
Registered Phase II clinical trials of R/R B-ALL in adults are currently underway and the data are robust
.
Figure 7 Results of Phase I clinical studies in Herkilens
Figure 8 Herkirensai Phase II clinical trial design
In view of the results of a large number of clinical studies, Herkirensai's new drug marketing application for adult r/r B-ALL indications is actively being prepared, and at the same time, the registered clinical study in children and adolescents (3-18 years old) r/r B-ALL patients has also obtained the clinical trial implied permission of the Drug Evaluation Center of the State Drug Administration on August 19, 2022, and the clinical trial is ongoing
.
It is believed that after the approval of the Hekylon Race for marketing, it will be able to fill the gap of targeted CD19 CAR-T treatment r/r B-ALL in China and bring hope
to more patients.
Professor Wang Jianxiang concluded
that Professor Wang Ying shared in detail the research status of r/r B-ALL therapy, the application of CAR-T therapy in r/r B-ALL, and the application of Heqirensai, the first Chinese targeted CD19 CAR-T therapy drug in R/r B-ALL
.
According to the relevant research and clinical cases of Hekylon race shared by Professor Wang Ying, we are full of confidence in the future clinical application of Hekylon race in r/r B-ALL! Editor: Su Meng Typesetting: Wenting Execution: Wenting
Poke "Read the original article" to see more
